HST5040 ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
245プロピオン酸血症1
246メチルマロン酸血症1

245. プロピオン酸血症


臨床試験数 : 13 薬物数 : 16 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 6
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04732429
(ClinicalTrials.gov)
March 15, 202121/1/2021Study of HST5040 in Subjects With Propionic or Methylmalonic AcidemiaA Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension StudyMethylmalonic Acidemia;Propionic AcidemiaDrug: HST5040;Drug: PlaceboHemoShear TherapeuticsNULLRecruiting2 YearsN/AAll12Phase 2United States;Australia

246. メチルマロン酸血症


臨床試験数 : 23 薬物数 : 31 - (DrugBank : 8) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04732429
(ClinicalTrials.gov)
March 15, 202121/1/2021Study of HST5040 in Subjects With Propionic or Methylmalonic AcidemiaA Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension StudyMethylmalonic Acidemia;Propionic AcidemiaDrug: HST5040;Drug: PlaceboHemoShear TherapeuticsNULLRecruiting2 YearsN/AAll12Phase 2United States;Australia